Episode Player

Market access in Italy: Reforms at AIFA

Pharma Market Access Insights - from Petauri Evidence

Chapters
2:03
Overview of Italian market for medicines
5:00
AIFA committees: the CTS, CPR and new CES
7:30
Planned changes at AIFA
13:29
Impact of changes, e.g. reduced number of committee members
20:56
How Pharma can respond to these changes, e.g. managed entry agreements
24:58
Impact of AIFA changes on advanced therapy / gene therapy / cell therapy products
27:16
Changes to early access programmes in Italy
31:00
Impact on Pharma market access and pricing strategy
33:06
Impact on the wider European landscape
39:06
Regional HTA in Italy
40:58
Strategic considerations for market access in Italy and Europe
Pharma Market Access Insights - from Petauri Evidence
Market access in Italy: Reforms at AIFA
Dec 18, 2023 Season 5 Episode 8
Mtech Access

Send us Fan Mail

Clare Foy (Director – Global Market Access, Mtech Access) speaks to Italian market access expert Prof. Fabrizio Gianfrate (Professor of Health Economics and Outcomes Research [HEOR] and Ex-Payer) about the market access landscape in Italy, particularly regarding changes at the Agenzia Italiana del Farmaco (AIFA).

We explore:
- The nature of the Italian market and the reimbursement process
- Pricing and market access considerations when launching in Italy
- What the reforms at AIFA mean for market access and managed entry agreements
- How the AIFA changes specifically impact innovative products
- Changes to early access programmes in Italy
- Impact of these changes on international pricing, particularly with the introduction of the EU Joint Clinical Assessment (JCA)

This episode was first broadcast as a live webinar in October 2023. Learn more at: https://mtechaccess.co.uk/italy-market-access-aifa-reforms/

Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence